Table 2.
Baseline predictors of experiencing first-time VA (n = 19) during 4.6 years of follow up in 94 LMNA genotype–positive patients without VA at study inclusion
| Univariable HR (95% CI) | P-value | Age-adjusted HR (95% CI) | P-value | |
|---|---|---|---|---|
| Age | 1.0 (1.0–1.1) | 0.01 | ||
| Proband | 3.8 (1.5–9.4) | 0.01 | 2.9 (1.2–7.5) | 0.02 |
| Female | 0.6 (0.3–1.5) | 0.30 | ||
| Non-missense mutation | 2.2 (0.3–16.4) | 0.45 | ||
| NSVT | 3.3 (1.3–8.2) | 0.01 | 2.0 (0.7–5.4) | 0.17 |
| Syncope | 0.6 (0.2–2.1) | 0.44 | ||
| Atrial fibrillation | 3.6 (1.4–9.7) | 0.01 | 2.1 (0.6–7.0) | 0.22 |
| AV block | 6.7 (2.1–21.1) | 0.001 | 4.9 (1.1–22.8) | 0.04 |
| ȃGrade I | 1.8 (0.6–5.4) | 0.33 | ||
| ȃGrades II and III | 5.3 (1.9–14.8) | 0.001 | 3.1 (0.9–10.6) | 0.08 |
| NYHA functional class ≥ II | 2.9 (1.2–7.2) | 0.02 | 1.9 (0.7–5.2) | 0.22 |
| LVEF, −5% | 1.3 (1.1–1.6) | 0.003 | 1.3 (1.0–1.5) | 0.02 |
| GLS, % | 1.2 (1.1–1.3) | 0.001 | 1.2 (1.1–1.4) | 0.001 |
| LV EDVi, 5 mL/m2 | 1.1 (1.0–1.2) | 0.01 | 1.1 (1.0–1.2) | 0.05 |
| LAVi, 5 mL/m2 | 1.1 (1.0–1.2) | 0.01 | 1.0 (0.9–1.2) | 0.46 |
| RVD, 5 mm | 1.2 (1.0–1.4) | 0.05 | 1.0 (0.9–1.3) | 0.68 |
| TAPSE, mm | 1.1 (1.0–1.2) | 0.02 | 1.1 (1.0–1.3) | 0.01 |
AV block, atrioventricular block; CI, confidence interval; GLS, global longitudinal strain; HR, hazard ratio; i, indexed values; LAV, left atrial volume; LV EDVi, left ventricular end-diastolic volume; LVEF, LV ejection fraction; NYHA, New York Heart Association; NSVT, non-sustained ventricular tachycardia; RVD, right ventricular diameter basal; TAPSE, tricuspid annular plane systolic excursion; VA, ventricular arrhythmia.